World’s first legal exporters of psilocybin solidifies partnership with acclaimed university in Canada for preclinical studiesRUNAWAY BAY, Jamaica, March 21,...
JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based...
New Program Targets Estimated $2.5 Billion Eye Pain MarketFREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”,...
Founder of Women In Nutraceuticals (WIN), Former VP of Numerous Industry Media Brands, and 30-Year Veteran of the Nutraceutical Industry...
FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical...
-Yield10 achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina -Omega-3 Camelina potentially represents...
Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to...
Over 20,000 surgical cases completed using Versius The versatile surgical robot Versius has now been used to perform over 20,000...
Achieves critical first step toward priority review voucherBASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq:...
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it...
Conference Call on Monday, April 1st, at 4:30 pm ETPOMPANO BEACH, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies...
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On...
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21,...
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health...
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform™ to increase gene expression using programmable, targeted medicines,...
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31,...
Figure 1 Dose escalation and subject numbers by dose since initiating the trial in March 2023 PYX-201 Phase 1 Part...
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient...